JP7009364B2 - ホモシスチン尿症の治療する組成物および方法 - Google Patents

ホモシスチン尿症の治療する組成物および方法 Download PDF

Info

Publication number
JP7009364B2
JP7009364B2 JP2018523444A JP2018523444A JP7009364B2 JP 7009364 B2 JP7009364 B2 JP 7009364B2 JP 2018523444 A JP2018523444 A JP 2018523444A JP 2018523444 A JP2018523444 A JP 2018523444A JP 7009364 B2 JP7009364 B2 JP 7009364B2
Authority
JP
Japan
Prior art keywords
htcbs
peg
pegylated
mice
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018523444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018532763A5 (enExample
JP2018532763A (ja
Inventor
ピー． クラウス、ジャン
マイタン、トーマス
ブブリル、エレズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Colorado Springs
Original Assignee
University of Colorado Colorado Springs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/935,690 external-priority patent/US9675678B2/en
Application filed by University of Colorado Colorado Springs filed Critical University of Colorado Colorado Springs
Publication of JP2018532763A publication Critical patent/JP2018532763A/ja
Publication of JP2018532763A5 publication Critical patent/JP2018532763A5/ja
Priority to JP2022002966A priority Critical patent/JP7482914B2/ja
Application granted granted Critical
Publication of JP7009364B2 publication Critical patent/JP7009364B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01022—Cystathionine beta-synthase (4.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2018523444A 2015-11-09 2016-11-09 ホモシスチン尿症の治療する組成物および方法 Active JP7009364B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022002966A JP7482914B2 (ja) 2015-11-09 2022-01-12 ホモシスチン尿症の治療する組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/935,690 2015-11-09
US14/935,690 US9675678B2 (en) 2013-01-29 2015-11-09 Compositions and methods for treatment of homocystinuria
PCT/US2016/061050 WO2017083327A1 (en) 2015-11-09 2016-11-09 Compositions and methods for treatment of homocystinuria

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022002966A Division JP7482914B2 (ja) 2015-11-09 2022-01-12 ホモシスチン尿症の治療する組成物および方法

Publications (3)

Publication Number Publication Date
JP2018532763A JP2018532763A (ja) 2018-11-08
JP2018532763A5 JP2018532763A5 (enExample) 2019-10-31
JP7009364B2 true JP7009364B2 (ja) 2022-02-10

Family

ID=58696136

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018523444A Active JP7009364B2 (ja) 2015-11-09 2016-11-09 ホモシスチン尿症の治療する組成物および方法
JP2022002966A Active JP7482914B2 (ja) 2015-11-09 2022-01-12 ホモシスチン尿症の治療する組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022002966A Active JP7482914B2 (ja) 2015-11-09 2022-01-12 ホモシスチン尿症の治療する組成物および方法

Country Status (26)

Country Link
US (3) US11077175B2 (enExample)
EP (3) EP4487914A3 (enExample)
JP (2) JP7009364B2 (enExample)
KR (1) KR102819396B1 (enExample)
CN (2) CN108472277A (enExample)
AU (2) AU2016354030B2 (enExample)
BR (1) BR112018007768A2 (enExample)
CA (1) CA3001625A1 (enExample)
CY (1) CY1125113T1 (enExample)
DK (2) DK3373922T3 (enExample)
ES (2) ES2909914T3 (enExample)
FI (1) FI3998067T3 (enExample)
HR (2) HRP20241491T1 (enExample)
HU (2) HUE058749T2 (enExample)
IL (2) IL302198A (enExample)
LT (2) LT3998067T (enExample)
MX (1) MX2018005312A (enExample)
NZ (1) NZ741552A (enExample)
PL (2) PL3373922T3 (enExample)
PT (2) PT3998067T (enExample)
RS (2) RS66106B1 (enExample)
SG (1) SG10201912972SA (enExample)
SI (2) SI3998067T1 (enExample)
SM (2) SMT202400463T1 (enExample)
WO (1) WO2017083327A1 (enExample)
ZA (1) ZA201802376B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
AU2016354030B2 (en) 2015-11-09 2022-09-15 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
MX2019012347A (es) 2017-04-17 2020-01-15 Univ Colorado Regents Optimizacion de terapia de reemplazo enzimatico para el tratamiento de la homocistinuria.
CN114786712A (zh) * 2019-06-26 2022-07-22 特拉维尔治疗瑞士有限公司 用于治疗高胱氨酸尿症的酶疗法的PEG化胱硫醚β合成酶
WO2021046190A1 (en) * 2019-09-03 2021-03-11 Orphan Technologies Ltd. Cystathionine beta-synthase enzyme therapy for treatment of elevated homocysteine levels

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014120770A1 (en) 2013-01-29 2014-08-07 The Regents Of University Of Colorado Cystathionine beta-synthase enzyme for treatment of homocystinuria

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS555429A (en) * 1978-06-23 1980-01-16 Nissan Motor Co Ltd Pressure regulator for fuel injection type gasoline engine
JPS5576559A (en) 1978-12-01 1980-06-09 Chiyou Lsi Gijutsu Kenkyu Kumiai Electron beam fine adjusting device
US5656425A (en) 1993-08-17 1997-08-12 Regents Of The University Of Colorado Screening for mutations by expressing cDNA segments
US5523225A (en) 1993-09-13 1996-06-04 Regents Of The University Of Colorado DNA sequence encoding human cystathionine β-synthase
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5635375A (en) 1995-01-09 1997-06-03 Regents Of The University Of Colorado Method of increasing the yield and heme saturation of cystathione β-synthase
EP1221615A2 (en) 1995-04-25 2002-07-10 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
US5705151A (en) 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
ES2224649T3 (es) 1998-04-28 2005-03-01 Applied Research Systems Ars Holding N.V. Conjugados de poliol-ifn-beta.
US6174696B1 (en) 1999-11-12 2001-01-16 Genzyme Corporation Method for the determination of homocysteine
AU5781800A (en) 1999-07-06 2001-01-22 General Atomics Methods and compositions for assaying analytes
US6653062B1 (en) 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
US20030091543A1 (en) 2001-10-26 2003-05-15 Klein Matthew B. Therapeutic cell preparation grafts and methods of use thereof
WO2003106971A2 (en) 2002-06-17 2003-12-24 The Regents Of The University Of Colorado HUMAN CYSTATHIONINE β-SYNTHASE VARIANTS AND METHODS OF PRODU CTION THEREOF
GB0216001D0 (en) 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
EP1396537A1 (en) * 2002-09-04 2004-03-10 Avidis SA Treatment of elevated plasma homocysteine
KR20060065663A (ko) 2003-07-31 2006-06-14 안티캔서, 인코포레이티드 생체 내에서의 유효성 향상을 위한, ＰＥＧ-ｒＭＥＴ아제와조합된 ＰＬＰ의 용도
CN1552905A (zh) 2003-12-18 2004-12-08 中国农业科学院茶叶研究所 一类茶树胱硫醚-γ-合成酶特异表达序列标签及其生物芯片
US8500720B2 (en) 2005-05-09 2013-08-06 Medtronic, Inc Method and apparatus for treatment of cardiac disorders
US20070010492A1 (en) 2005-07-11 2007-01-11 Generale Robert J Composition and method for reducing homocysteine caused by drugs containing methyl compounds
EP1878739A1 (en) 2006-07-14 2008-01-16 LEK Pharmaceuticals D.D. One step IMAC (MCAC) purification of proteins
JP6041454B2 (ja) * 2007-03-15 2016-12-07 株式会社 Ｄｎａセキュリティー研究所 Ｄｎａ含有インク組成物
JP5074146B2 (ja) 2007-03-30 2012-11-14 オリンパス株式会社 カプセル型医療装置
CN101322840A (zh) 2008-05-28 2008-12-17 中国人民解放军军事医学科学院卫生学环境医学研究所 一种人胱硫醚β-合成酶重组蛋白及应用
CA2771575A1 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
WO2011097381A2 (en) 2010-02-04 2011-08-11 The Board Of Regents Of Use University Of Texas System Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations therof
US9364497B2 (en) 2010-07-01 2016-06-14 Isis Innovation Limited Treatment of cognitive disorders
US9243239B2 (en) 2012-03-26 2016-01-26 The Regents Of The University Of Colorado, A Body Corporate Purification of cystathionine beta-synthase
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
WO2015033279A1 (en) * 2013-09-04 2015-03-12 Mahesh Kandula Compositions and methods for the treatment of homocystinuria
CN108026143B (zh) 2015-07-24 2022-05-27 韩美药品株式会社 制备生理活性多肽缀合物的方法
AU2016354030B2 (en) 2015-11-09 2022-09-15 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
MX2019012347A (es) 2017-04-17 2020-01-15 Univ Colorado Regents Optimizacion de terapia de reemplazo enzimatico para el tratamiento de la homocistinuria.
JP7002314B2 (ja) * 2017-12-13 2022-02-10 株式会社ブリヂストン 空気入りタイヤ
CN114786712A (zh) 2019-06-26 2022-07-22 特拉维尔治疗瑞士有限公司 用于治疗高胱氨酸尿症的酶疗法的PEG化胱硫醚β合成酶
WO2021046190A1 (en) 2019-09-03 2021-03-11 Orphan Technologies Ltd. Cystathionine beta-synthase enzyme therapy for treatment of elevated homocysteine levels

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014120770A1 (en) 2013-01-29 2014-08-07 The Regents Of University Of Colorado Cystathionine beta-synthase enzyme for treatment of homocystinuria

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Inherit. Metab. Dis.，2015年08月01日，Vol.39，pp.39-46

Also Published As

Publication number Publication date
IL302198A (en) 2023-06-01
EP3373922A4 (en) 2019-05-15
ES2994256T3 (en) 2025-01-21
PT3373922T (pt) 2022-03-28
IL258487B1 (en) 2023-05-01
EP3998067A1 (en) 2022-05-18
HRP20241491T1 (hr) 2025-01-03
KR20180074703A (ko) 2018-07-03
JP7482914B2 (ja) 2024-05-14
SI3998067T1 (sl) 2025-03-31
AU2022287540A1 (en) 2023-02-02
CN115920016A (zh) 2023-04-07
HUE058749T2 (hu) 2022-09-28
WO2017083327A1 (en) 2017-05-18
RS66106B1 (sr) 2024-11-29
PL3373922T3 (pl) 2022-05-02
LT3373922T (lt) 2022-04-11
AU2016354030A1 (en) 2018-05-10
BR112018007768A2 (pt) 2018-10-23
EP3373922A1 (en) 2018-09-19
EP3373922B1 (en) 2022-01-05
KR102819396B1 (ko) 2025-06-12
HRP20220407T1 (hr) 2022-05-27
CA3001625A1 (en) 2017-05-18
EP3998067B1 (en) 2024-09-11
US20240091325A1 (en) 2024-03-21
SG10201912972SA (en) 2020-03-30
PT3998067T (pt) 2024-11-04
EP4487914A3 (en) 2025-03-26
US12194082B2 (en) 2025-01-14
US20200276282A1 (en) 2020-09-03
SI3373922T1 (sl) 2022-05-31
DK3998067T3 (da) 2024-10-28
SMT202200151T1 (it) 2022-05-12
AU2016354030B2 (en) 2022-09-15
JP2022050589A (ja) 2022-03-30
CN108472277A (zh) 2018-08-31
SMT202400463T1 (it) 2025-01-14
HUE068830T2 (hu) 2025-01-28
CY1125113T1 (el) 2024-02-16
MX2018005312A (es) 2018-08-15
ZA201802376B (en) 2020-11-25
IL258487A (en) 2018-05-31
US11771745B2 (en) 2023-10-03
LT3998067T (lt) 2024-11-25
IL258487B2 (en) 2023-09-01
US11077175B2 (en) 2021-08-03
PL3998067T3 (pl) 2025-01-07
DK3373922T3 (da) 2022-03-28
FI3998067T3 (fi) 2024-10-31
JP2018532763A (ja) 2018-11-08
RS63070B1 (sr) 2022-04-29
ES2909914T3 (es) 2022-05-10
NZ741552A (en) 2022-04-29
AU2022287540B2 (en) 2025-02-27
EP4487914A2 (en) 2025-01-08
US20220125896A1 (en) 2022-04-28
HK1258502A1 (en) 2019-11-15

Similar Documents

Publication Publication Date Title
JP7482914B2 (ja) ホモシスチン尿症の治療する組成物および方法
US10653755B2 (en) Compositions and methods for treatment of homocystinuria
JP2023123565A (ja) 治療用組換えクロトータンパク質ならびにそれを含む組成物および方法
US10624959B2 (en) Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
CN114786712A (zh) 用于治疗高胱氨酸尿症的酶疗法的PEG化胱硫醚β合成酶
CN118064414A (zh) 治疗同型半胱氨酸尿症的酶替代疗法优化
HK40072007B (en) Compositions and methods for treatment of homocystinuria
HK40072007A (en) Compositions and methods for treatment of homocystinuria
US20210267939A1 (en) Compositions and methods for treating nafld/nash and related disease phenotypes
HK1258502B (en) Compositions and methods for treatment of homocystinuria
WO2025193499A1 (en) Compositions and methods to potentiate enzyme therapies for treating homocystinuria and homocysteine remethylation disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210330

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210927

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211214

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220112

R150 Certificate of patent or registration of utility model

Ref document number: 7009364

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250